Is there a role for RDTs as we live with COVID-19? An assessment of different strategies
Introduction By 2022, high levels of past COVID-19 infections, combined with substantial levels of vaccination and the development of Omicron, have shifted country strategies towards burden reduction policies. SARS-CoV-2 rapid antigen tests (rapid diagnostic tests (RDTs)) could contribute to these p...
Main Authors: | Mark Jit, Anna Vassall, Gabrielle Bonnet |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-01-01
|
Series: | BMJ Global Health |
Online Access: | https://gh.bmj.com/content/8/1/e010690.full |
Similar Items
-
Modelling costs and benefits of RDTs for the detection of Plasmodium falciparum in Uganda
by: Lubell, Y, et al.
Published: (2007) -
Access to and utilization of COVID-19 antigen rapid diagnostic tests (Ag-RDTs) among people living with HIV (PLWH): A mixed methods study from Cambodia
by: Kennarey Seang, et al.
Published: (2024-01-01) -
Exploiting the Potential of Magnetic Nanoparticles for Rapid Diagnosis Tests (RDTs): Nanoparticle-Antibody Conjugates and Color Development Strategies
by: Yeonjeong Ha
Published: (2023-09-01) -
Data set on Rapid Diagnostic Tests (RDTs) and microscopy for diagnosing plasmodium falciparum and plasmodium vivax
by: Grace I. Olasehinde, et al.
Published: (2018-10-01) -
Diagnostic Performance of Ag-RDTs and NAAT for SARS-CoV2 Identification in Symptomatic Patients in Catalonia
by: Luca Basile, et al.
Published: (2021-05-01)